As part of a corporate restructuring, Valcare Medical has appointed Chad Sandweg as Chief Executive Officer. Sandweg brings a successful 25-year history in the medical device space, having worked for both Fortune 500 and startup companies in the cardiovascular and structural heart space. He most recently served as Chief Commercial Officer for EBR Systems, Inc., the developer of the world’s only wireless cardiac pacing system for heart failure.
Prior to that, Sandweg held leadership positions at Keystone Heart and Direct Flow Medical. He began his cardiovascular and structural heart career with Medtronic Corp. in 2006, where he played a key role in the successful launch of several strategic products.
“I’m excited and honored to be joining such a remarkably talented team,” said Sandweg. “The corporate restructure offers a unique opportunity for us to increase focus and accelerate performance.”
Valcare Medical has also appointed a new Board of Directors led by Executive Board Chair Steve Richardson. Richardson has over 30 years of experience in the medical device industry and a proven track record of successfully leading medtech startups through clinical study phase, regulatory approval, commercial launch, and acquisition.
“We’re fortunate to have Steve come on board at this important stage in Valcare’s development,” said Sandweg. “Steve has the experience and operational track record the company needs at this time to execute on its ambitious plan to transform the standard of care for patients suffering from severe mitral regurgitation.”
Valcare’s AMEND mitral valve repair device is an innovative, clinically proven, D-shaped, semi-rigid closed ring with proprietary anchoring capabilities. AMEND is designed to provide clinical standard-of-care surgical treatment via a transcatheter-based procedure. The AMEND platform also serves as the foundation for Valcare’s future mitral replacement and tricuspid repair solutions.
Valcare Medical is dedicated to providing innovative minimally invasive technologies for the treatment of mitral regurgitation.
